ChemoCentryx, Inc. (NASDAQ:CCXI) Q3 2019 Earnings Conference Call - Final Transcript

Nov 04, 2019 • 05:00 pm ET

Previous

ChemoCentryx, Inc. (NASDAQ:CCXI) Q3 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

Thank you, sir. [Operator Instructions] Your first question is from Steve Seedhouse from Raymond James.

Analyst
Steve Seedhouse

Hi guys, good afternoon. Thank you. Looking forward to data later this quarter. My first question is, can you share the split or the rough split or qualify in some way, how many patients would have received rituximab or cyclophosphamide and ADVOCATE, even if it's on a blinded basis or if not was there anything in the protocol to ensure a minimum number of patients on either of those regimens?

Executive
Thomas J. Schall

Steve more details to come, of course, I don't have the exact details to give to you today. I will say this, that we modeled the rituximab cyclophosphamide usage pretty much how the geography where the trial was going to be mapped out, so approximately about 1.25 or 1.3 rituximab to every 0.6 or so cyclophosphamide just given the global distribution. And so I have no reason to believe that will be two variant from that, but I just don't have the details at this moment.

Analyst
Steve Seedhouse

Okay, that's still helpful. Thanks, Tom. And could you maybe also on the secondary endpoints speak to which of those on the entire list or whichever ones you might highlight are adequately powered to hit a nominal p.05 and which may not be powered for that type of nominal P-value, even if the result there's avacopan numerically or are they all theoretically well powered?

Executive
Thomas J. Schall

I think the short answer is all theoretically well powered rather and of course, the details are, for example, when you have quality of life, you actually have several categories within quality of life. And so the question is, is there a way to -- can you talk about those in aggregate? Or do you talk about the categories individually? In Phase II, we talked about categories more or less individually. It was -- but it was very clear six of eight of those categories in the SF-36 by way of example was statistically p<0.5 in advantage to avacopan relative to the baseline readings and relative to the standard of care.

So we're fairly optimistic that with the larger end and in the ADVOCATE trial will be able to show reasonable P-values across a number of very important secondary endpoints. And in short we tried to power the numbers appropriately to at least show folks, where we thought we were seeing meaningful benefit in some of those in areas.

Analyst
Steve Seedhouse

Okay, thank you. And are there any milestones from your partner associated with Phase III either hitting the primary endpoint or subsequently filing for approval or subsequently approval that we should be aware of?

Executive
Thomas J. Schall

Susan, I'll let you take that question.

Executive
Susan M. Kanaya

Sure, Steve. The milestones are not tied to clinical, but R&D tied to regulatory events.

Analyst
Steve Seedhouse

Okay. And are you able to disclose ranges or what those amounts would be?

Executive
Susan M. Kanaya

No, we haven't done so, but I think the CMA, give you a guide at least for one piece, but tied to approval would be there likely